Gilead (GILD) Q4 2025: Yes2Go Set for $800M Surge, Pivots HIV Prevention Growth Trajectory

2026-02-10 | By EarningsIQ Research

Gilead’s 2025 closed with HIV prevention momentum as Yes2Go’s rapid uptake and blockbuster trajectory signal a new growth engine for 2026. Management’s outlook emphasizes four potential launches and pipeline breadth, while navigating policy headwinds and cell therapy drag. Investors should focus on the durability of HIV franchise growth, the operational discipline supporting margin strength, and the expanding clinical catalyst calendar into 2027.

Summary

• HIV Prevention Inflection: Yes2Go’s rapid adoption and blockbuster outlook shift the HIV business profile.
• Pipeline Catalysts Accelerate: Four launches and five pivotal readouts in 2026 expand Gilead’s diversification strategy.
• Margin and Cash Discipline: Operating leverage and capital returns provide ballast amid cell therapy headwinds.

Business Overview

Gilead Sciences is a global biopharmaceutical company focused on antiviral and oncology therapies. The company’s revenue is anchored by its HIV franchise—including treatment and prevention drugs—alongside liver disease, oncology, and cell therapy segments. Gilead generates revenue through branded pharmaceuticals, with HIV products (treatment and prevention) representing the majority of sales, complemented by liver disease drugs (notably Livdelzy), oncology agents (such as Trodelvi), and cell therapies (via KITE).

Performance Analysis

Gilead delivered robust top-line growth in 2025, led by HIV and liver disease franchises, while cell therapy revenue declined as expected due to competitive pressures. Excluding COVID-related Vecluri, base business sales exceeded guidance, reflecting both underlying demand and pricing strength in core products. The HIV business, which comprises the largest share of revenue, grew despite a significant Medicare Part D redesign headwind, with Biktarvy and prevention brands (notably Yes2Go and Descovy) outperforming expectations. Liver disease revenue was buoyed by Livdelzy’s rapid adoption, while oncology sales, particularly Trodelvi, benefited from positive clinical data and guideline inclusion.

Margin performance remained resilient, with disciplined R&D and SG&A spending supporting operating leverage. Gross margin held steady, and operating margin approached 48% (excluding acquired R&D), demonstrating Gilead’s ability to fund launches while maintaining profitability. The company returned over 60% of free cash flow to shareholders, balancing investment and capital return.

• HIV Franchise Resilience: Biktarvy’s share gains and Yes2Go’s launch offset policy headwinds, with prevention up 53% YoY.
• Livdelzy Drives Liver Growth: Sequential and YoY acceleration as competitor withdrawal consolidates market share.
• Cell Therapy Drag: KITE revenues fell 7% YoY, with further 10% decline guided for 2026 amid new entrants and trial-driven volume shifts.

Gilead’s performance underscores the durability of its HIV platform, the growing contribution of new launches, and the operational discipline that supports both growth and capital allocation flexibility.

Executive Commentary

Strategic Positioning

1. HIV Prevention as a Growth Engine

Yes2Go, the biannual injectable for HIV prevention, is positioned as a transformative product within Gilead’s portfolio. Management expects Yes2Go to reach $800 million in 2026 revenue, up from $150 million in 2025, with 90% payer coverage and a direct-to-consumer campaign accelerating adoption. This not only diversifies the HIV business but also expands Gilead’s addressable market as awareness and access broaden.

2. Pipeline Launch Cadence and Diversification

Gilead is targeting four potential product launches in 2026, spanning HIV, oncology, and liver disease, with up to 10 launches through 2027. Notable near-term catalysts include Trodelvi’s expansion into first-line metastatic triple negative breast cancer, Biclen (a new HIV oral regimen), Anitocel for multiple myeloma, and bulevirtide for hepatitis delta. This launch cadence reflects a deliberate shift from legacy reliance on HIV treatment toward a more diversified, innovation-driven portfolio.

3. Operational and Cost Discipline

Expense management remains a strategic priority, with SG&A and R&D held flat or declining YoY despite increased launch activity. Gilead continues to return a majority of free cash flow to shareholders while funding new launches, reflecting a balance between growth investment and capital returns.

4. Business Development and Pipeline Augmentation

Management reiterated a steady cadence of early-stage dealmaking (about $1 billion annually) and a disciplined approach to larger M&A. With no major loss of exclusivity (LOE) until 2036, Gilead is not under pressure for transformative M&A, but remains proactive in supplementing its pipeline across core therapeutic areas.

5. Navigating Policy and Competitive Headwinds

Policy changes (Medicare Part D, Medicaid pricing, ACA channel shifts) create near-term growth headwinds, especially in HIV. Management expects a 2% drag on 2026 HIV growth from these factors, but underlying demand trends remain robust. In cell therapy, competitive intensity and new clinical trials are expected to pressure volume and revenue through 2026.

Key Considerations

This quarter marks a strategic inflection for Gilead as Yes2Go’s performance validates the company’s long-term prevention thesis and pipeline launches accelerate diversification.

Key Considerations:

• Yes2Go’s Blockbuster Ramp: The $800 million 2026 target is underpinned by payer coverage, DTC campaigns, and operational pull-through, with persistency and refill rates as emerging metrics to watch.
• HIV Franchise Durability: Biktarvy’s continued share gains and Descovy’s resilience suggest the core HIV business remains robust, even as prevention cannibalizes oral PrEP over time.
• Pipeline Execution Risk: Four launches and five pivotal readouts in 2026 create both upside optionality and execution complexity across regulatory, reimbursement, and commercial fronts.
• Cell Therapy Headwinds: KITE’s revenue decline signals ongoing competitive and clinical trial pressures, with management guiding for a further 10% drop in 2026.
• Policy Drag on Growth: Drug pricing reforms and ACA changes are expected to impact HIV growth by 2% in 2026, requiring continued commercial and pricing discipline.

Risks

Key risks include further pricing pressure from U.S. policy changes, competitive intensity in cell therapy and HIV prevention, and operational complexity from a crowded launch calendar. Delays or setbacks in pipeline readouts or regulatory approvals could impact the pace of diversification. While management is disciplined on M&A, the need to replenish long-term growth beyond the current pipeline remains an ongoing strategic necessity.

Forward Outlook

For Q1 2026, Gilead expects:

• Seasonal HIV inventory drawdown to weigh on sequential growth
• Continued Yes2Go ramp with incremental market access and DTC impact

For full-year 2026, management guided:

• Total product sales of $29.6–$30 billion
• Base business (ex-Vecluri) sales of $29–$29.4 billion, up 4–5%
• HIV growth of approximately 6% (8% excluding policy headwinds)
• Yes2Go revenue of $800 million
• Cell therapy revenue to decline about 10% YoY
• Non-GAAP EPS of $8.45–$8.85

Management highlighted:

• Four potential product launches and five pivotal pipeline readouts in 2026
• Ongoing capital returns, with at least 50% of free cash flow targeted for shareholders

Takeaways

Gilead’s 2025 results and 2026 guidance reinforce a strategic pivot toward prevention-driven HIV growth and pipeline-led diversification.

• Yes2Go’s rapid adoption is reshaping the HIV prevention landscape and providing a new growth vector for Gilead’s largest franchise.
• Disciplined cost management and capital allocation underpin margin strength and support aggressive launch investment without compromising returns.
• Investors should monitor execution on the crowded 2026 launch and readout calendar, as well as signals of pipeline sustainability and cell therapy stabilization.

Conclusion

Gilead enters 2026 with clear momentum in HIV prevention, a robust launch calendar, and operational discipline that supports both growth and shareholder returns. The evolving mix—anchored by Yes2Go and pipeline catalysts—positions the company for durable growth, though competitive and policy headwinds require ongoing vigilance.

Industry Read-Through

Gilead’s Yes2Go trajectory signals a major inflection in the HIV prevention market, with long-acting injectables poised to expand the addressable population and shift payer dynamics across the sector. The company’s launch cadence and pipeline breadth raise the bar for innovation-driven growth among large-cap biopharma peers, while its operational discipline and capital allocation highlight the importance of margin leverage amid increasing policy headwinds. Cell therapy’s competitive drag serves as a cautionary signal for other players facing new entrants and trial-driven volume shifts. The sector should watch for further pricing reforms and the impact of prevention-focused strategies on legacy treatment franchises.

GILD Healthcare Biotechnology HIV Oncology Cell therapy Pipeline Prevention